Correlation between the expression of Livin and the prognosis of nasopharyngeal carcinoma after radiother-apy
Abstract:Objective To explore the relationship between the expression of Livin and the prognosis of nasopharyngeal carci-noma after radiotherapy. Methods A total of 114 nasopharyngeal cancer patients who received radiotherapy for the first time were en-rolled in this study. Before treatment, the expression of Livin in nasopharyngeal carcinoma tissues was detected by immunohistochemical SP method. The relationship between the expression of Livin and the short-/long-term efficacy, as well as clinicopathological features of nasopharyngeal carcinoma was observed. Cox hazard-regression model was used to analyze the factors influencing overall survival ( OS) and progression-free survival ( PFS) . Results The positive expression rate of Livin protein in 114 patients with nasopharyngeal carci-noma was 65. 8% ( 75/114) . The response rate was 94. 9% ( 37/39) in patients with negative Livin expression after radiotherapy, and it was 72. 0% ( 54/75) in patients with positive Livin expression after radiotherapy. The expression of Livin was related to clinical stag-ing, cervical lymph node metastasis, N-staging and T-staging ( P<0. 05) , but not to age and gender ( P>0. 05) . The 5-year survival rate and 5-year progression-free survival rate were 53. 3% and 48. 0% of patients with positive Livin expression, lower than 92. 3% and 87. 2% of patients with negative Livin expression (P<0. 05). Cox hazard-regression model showed that expression of Livin, clinical staging and N-staging were independent risk factors affecting OS after radiotherapy for patients with nasopharyngeal carcinoma, and Livin expression and clinical staging were the independent risk factors influencing PFS. Conclusion The expression of Livin is associ-ated with the prognosis of nasopharyngeal carcinoma, and it may be used as an indicator for the prognosis of nasopharyngeal carcinoma.
Keywords:Nasopharyngeal carcinomaApoptosis inhibitory proteinLivinRadiotherapyPrognosisImmuno-histochemistry
Publication Date:2016-01-01
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:5( 985-989 )
Chinese Clinical Oncology

Chinese Clinical Oncology

PKUISTIC
ISSN:1009-0460
Year, Vol.(Issue):2016,21(11)